Neuren Pharmaceuticals
NEU.AX
#5556
Rank
โ‚น82.25 B
Marketcap
โ‚น636.34
Share price
-2.69%
Change (1 day)
-45.33%
Change (1 year)

P/E ratio for Neuren Pharmaceuticals (NEU.AX)

P/E ratio at the end of 2023: 18.6

According to Neuren Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 8.8291. At the end of 2023 the company had a P/E ratio of 18.6.

P/E ratio history for Neuren Pharmaceuticals from 2005 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202318.6-99.62%
2022> 1000-9881.16%
2021-50.0305.04%
2020-12.4-40.3%
2019-20.7-147%
201844.0-132.48%
2017-1361776.77%
2016-7.22-41.75%
2015-12.4-25.57%
2014-16.789.19%
2013-8.8078.92%
2012-4.9281.44%
2011-2.71248.05%
2010-0.7792-101.24%
200962.9-47387.89%
2008-0.1331-90.93%
2007-1.47-58.92%
2006-3.57-34.95%
2005-5.49

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.